The Wuxi International Life Science Innovation Campus, also known as I-Campus, makes its debut at this year's China International Import Expo in Shanghai on Nov 6. [Photo/people.com.cn]
The Wuxi International Life Science Innovation Campus, also known as I-Campus, made its debut at this year's China International Import Expo in Shanghai on Nov 6.
The I-Campus was constructed by AstraZeneca, the Wuxi government, and the government of the Wuxi National Hi-Tech District. During its opening, the campus signed an agreement with the Australian Trade and Investment Commission to attract more investment and cooperation.
CICC Capital also signed an agreement with AstraZeneca to offer financial support to companies located in the I-Campus.
The I-Campus project deal was signed during this year's Boao Forum for Asia and launched in September. It represents another attempt by AstraZeneca to build an incubation platform for early research and development, the industrialization of research findings, the display of intelligent products, and the development of professional services in the life sciences sector.
Wang Jinjian, vice mayor of Wuxi, said that Wuxi has been working for years to develop life science industries. As a result, a bio-pharmaceutical industry cluster based around innovative drugs, medical devices, smart medical care, and health services has been built in Wuxi.
AstraZeneca China CEO Wang Lei noted that the I-Campus is expected to become a platform for promoting global cooperation and innovation in the life science industry.
The I-Campus's exhibition area featured four pieces of innovative equipment during the 2nd CIIE, including an "artificial heart" miniature human-heart multilayer bioreactor developed by Hong Kong company Novoheart.
